Aptevo's CD40 solid-tumour trio stays preclinical, with two set for 2027 development step

Aptevo Therapeutics has put a timeline on its CD40 solid-tumour ambitions: two of three preclinical molecules are expected to move into IND-enabling studies in 2027. The company announced on 9 November that it had presented the work at the Society for Immunotherapy of Cancer annual meeting two days earlier. It disclosed no financial terms, partnering plans or funding linked to the programmes.

The three candidates are APVO451, APVO452 and APVO711. According to Aptevo, the first two pair CD40 activation with T-cell engagement and killed tumour cells in experiments run under immunosuppressive conditions. APVO711 combines CD40 activation with PD-L1 blockade, and the company said it activated immune cells.

Little else was provided. The announcement as summarised does not say which two molecules will advance, which tumour types or models were used, or what the quantitative results were. All of the findings come from the company itself and are preclinical, so they say nothing about safety or efficacy in patients.

No regulatory filing or agency contact has been reported. An IND application would come only after the 2027 enabling work, which makes that step the next milestone for outside observers to track.